ETC
YMAB

Exchange Traded Concepts’s Y-mAbs Therapeutics YMAB Stock Holding History

Exchange Traded Concepts’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,762
Closed -$119K – 1518
2025
Q1 		$119K Buy
26,762
+13,890
+108% +$80.6K ﹤0.01% 1095
2024
Q4 		$101K Hold
12,872
– – ﹤0.01% 1141
2024
Q3 		$169K Sell
12,872
-1,617
-11% -$20.5K ﹤0.01% 1015
2024
Q2 		$175K Sell
14,489
-4,507
-24% -$60.8K ﹤0.01% 889
2024
Q1 		$309K Sell
18,996
-9,099
-32% -$123K 0.01% 788
2023
Q4 		$192K Buy
28,095
+7,124
+34% +$41.2K 0.01% 792
2023
Q3 		$114K Buy
20,971
+4,763
+29% +$27.7K ﹤0.01% 855
2023
Q2 		$110K Buy
+16,208
New +$121K ﹤0.01% 933

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Exchange Traded Concepts's YMAB Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 26,762 shares — an estimated $119K sold.

Exchange Traded Concepts first reported a position in YMAB in Q2 2023 and held it in 8 quarters. The position peaked at $309K in Q1 2024. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 26,762 Y-mAbs Therapeutics shares in Q2 2025, an estimated $119K.
  • Exchange Traded Concepts first reported a position in Y-mAbs Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Y-mAbs Therapeutics position peaked at $309K in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.